# Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors

Source: https://onco.cc/trials/nct06975410/  
OnCo record `nct06975410` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of YH32364 in advanced solid tumours, run by Yuhan Corporation, now recruiting.

## Summary

Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors is a phase 1/2 interventional study registered as NCT06975410 by Yuhan Corporation, with 80 participants planned, started 2025-06-12 and due to reach its primary completion in 2027-06. Interventions recorded: YH32364.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06975410
- Phase: 1/2
- Setting: A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32364 in Patients With Locally Advanced or Metastatic Solid Tumors
- Sponsor: Yuhan Corporation
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT06975410: https://clinicaltrials.gov/study/NCT06975410

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06975410.json